AD, PD, HD, ALS, Stroke, MS, PTSD, DMD, SCA, BattenPsychiatry 

Schizophrenia, Depression, AnxietyPain 

Neuropathic-Chung, CCI, Visceral-Endometriosis, Bladder, Chemotherapy-induced pain, Central PainOncology

Syngenic Melanoma, Xenograph,  Pancreatic Cancer, Glioblastom

Eye Diseases
Dry eye disease, AMD

Metabolic diseases

NASH, DiabetesSafety & Toxicology
Mouse, rat, canine, pig, NHP, ADME PK

Jonathan E. Friedman  PhD  >>>


Larry Chong Park  PhD  >>>

Founder & CEO

Patrick is co-founder and COO of Naason Science Inc. He has served as CEO, Managing Director of Neurology and Director of Business Development at Charles River Finland. Prior to that he founded a CNS focussed CRO which got acquired by Charles River. He has unparalleled experience in the discovery and development of new drugs, with a particular focus on the CNS.

Kati Sweeney  BBA, MSc  >>>

Director of Marketing

150+ Years of Cumulative CRO and Preclinical Drug Development Experience located in two world class cutting-edge centers of Osong Bio-medical Science Complex in Osong and DGMIF in Daegu, South Korea.

Please do not hesitate to contact us info@naasonscience.com if you have any questions about our products and services. ​      

​>> Naason Team 

Our personal email addresses are in form firstname[at]naasonscience.com.

Kyung Ho Park  DVM  >>>

Team leader

Patrick J. Sweeney PhD, MBA

Founder & COO

Naason Science CRO (Contract Research Organization) - Where the next generation of preclinical research begins!Faster, better decisions - Based on knowledge of drug discovery and outsourcing experience, building the best integrated global preclinical services with an emphasis on innovation, reliability and commitment. Naason´s various preclinical modelling platforms are customized to suite the needs of drug developers. The platforms can accommodate all drug delivery routes as well as preclinical proof-of-concept for medical devices. From in vitro systems to large and small animal in vivo models Naason Science provides a tool box of state-of-the-art technologies the allow for rapid and effective testing of preclinical drug candidates.​​ ​The Naason process starts from an in-depth knowledge of the demands of global pharmaceutical development. It involves combining superior knowledge of biological systems and system dynamics with the latest preclinical disease models, highlighting the comparative and translatable aspects and using this data to highlight the way forward for a particular drug or a drug development platform. ​The data generated from our preclinical modelling platforms is designed to provide pertinent insight and better translatability in order to allow for easier decisions made faster. Faster decision making allows a reduction in the cost of research and development. Naason Science provides the tools to study neurology, oncology, cardiovascular and metabolic therapies in a way that allows faster and better decisions. Let us show you !

Naason Science Mail
Naason Science LinkedIn
Naason Science Facebook